Yi Ren,
PhD

Dr. Ren is General Manager of Nanjing Medichem Biopharmaceutical Development Co. and General Manager and member of the board of directors of Chizhou Ruick Pharmaceutical Co. Previously, he was senior director and head of CMC at Roche R&D China and part of the core leadership team for Roche API, Formulation, Small Molecule R&D, Virology R&D, and China R&D. He has extensive experience in R&D, manufacturing, commercialization of generic drugs, and innovative pharmaceuticals, and is a co-inventor of Zelboraf, a novel treatment of malignant melanoma. Dr. Ren holds a PhD. degree in Organic Chemistry from the University of Toronto; postdoc training at the University of Michigan, and an MBA from Rutgers University in the United States.